Systemic Therapy for Hidradenitis Suppurativa: Real-World Outcomes
Key Findings
Biologic therapy achieved 63% HiSCR response at 16 weeks in real-world setting. Quality of life improved significantly.
Summary
Biologic therapy achieved 63% HiSCR response at 16 weeks in real-world setting. Quality of life improved significantly.
Study Design
Multicenter registry analysis of 850 patients with moderate-to-severe hidradenitis suppurativa receiving biologics.
Methods
Patients treated with TNF-alpha or IL-17 inhibitors. Outcomes: HiSCR, pain scores, quality of life, adverse events.
Results
HiSCR at 16 weeks: 63%. Pain NRS reduction: 42%. DLQI improved 58%. Treatment persistence: 78% at 1 year.
Conclusions
Biologic therapy effective for hidradenitis suppurativa in real-world practice with sustained benefits and good retention.
Full Abstract
This study examined systemic therapy for hidradenitis suppurativa: real-world outcomes in a comprehensive clinical investigation.